Inventor · disambiguated record
Xin Chen
Also filed as: CHEN XIN · Chen xin-wen
76 granted patents·49 pending applications·544 citations·filing 1998–2025
99Inventor score
Top patents by PatentIndex Score
125 records- 0197US11085076B2Synthesis of novel disulfide linker based nucleotides as reversible terminators for DNA sequencing by synthesisJU JINGYUE·Filed 2016·Granted Aug 10, 2021·19 cites·15 claims
- 0297US10730870B2Compounds and methods for the enhanced degradation of targeted proteinsARVINAS INC·Filed 2016·Granted Aug 4, 2020·25 cites·22 claims
- 0396US11999999B2Synthesis of novel disulfide linker based nucleotides as reversible terminators for DNA sequencing by synthesisJU JINGYUE·Filed 2021·Granted Jun 4, 2024·19 cites·21 claims
- 0496US7638541B25-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidineMETABOLEX INC·Filed 2007·Granted Dec 29, 2009·43 cites·2 claims
- 0596US7361678B2Azole derivatives and fused bicyclic azole derivatives as therapeutic agentsTRANSTECH PHARMA INC·Filed 2003·Granted Apr 22, 2008·113 cites·24 claims
- 0695US7700594B2Fused bicyclic mTOR inhibitorsOSI PHARM INC·Filed 2006·Granted Apr 20, 2010·38 cites·6 claims
- 0793US8476308B2GPR120 receptor agonists and uses thereofMETABOLEX INC·Filed 2012·Granted Jul 2, 2013·12 cites·6 claims
- 0893US7432394B2Resolution of α-(phenoxy) phenylacetic acid derivatives with naphthyl-alkylaminesMETABOLEX INC·Filed 2006·Granted Oct 7, 2008·12 cites·21 claims
- 0991US11708366B2Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereofNOVARTIS AG·Filed 2021·Granted Jul 25, 2023·2 cites·27 claims
- 1091US8227495B22,4-disubsituted thiazoles and pharmaceutical compositions thereofCHEN XIN·Filed 2009·Granted Jul 24, 2012·13 cites·18 claims
- 1191US7923555B2Fused bicyclic mTor inhibitorsOSI PHARM INC·Filed 2008·Granted Apr 12, 2011·15 cites·2 claims
- 1291US7737285B2Azole derivatives and fused bicyclic azole derivatives as therapeutic agentsTRANSTECH PHARMA INC·Filed 2007·Granted Jun 15, 2010·15 cites·4 claims
- 1391US7714013B2Azole derivatives and fused bicyclic azole derivatives as therapeutic agentsTRANSTECH PHARMA INC·Filed 2006·Granted May 11, 2010·18 cites·14 claims
- 1490US12503730B2Detectable nucleotide analoguesUNIV COLUMBIA·Filed 2024·Granted Dec 23, 2025·0 cites·20 claims
- 1590US11485742B22-azaspiro[3.4]octane derivatives as M4 agonistsNOVARTIS AG·Filed 2020·Granted Nov 1, 2022·2 cites·22 claims
- 1690US7714131B2Process for the stereoselective preparation of (−)-halofenate and derivatives thereofMETABOLEX INC·Filed 2006·Granted May 11, 2010·9 cites·16 claims
- 1789US11548865B22-azaspiro[3.4]octane derivatives as M4 agonistsNOVARTIS AG·Filed 2020·Granted Jan 10, 2023·2 cites·29 claims
- 1889US8314111B2Fused bicyclic motor inhibitorsCHEN XIN·Filed 2011·Granted Nov 20, 2012·12 cites·2 claims
- 1989US8288384B2Heterocyclic receptor agonists for the treatment of diabetes and metabolic disordersCHEN XIN·Filed 2009·Granted Oct 16, 2012·9 cites·1 claims
- 2088US11352351B2Compounds and methods for the targeted degradation of androgen receptorARVINAS INC·Filed 2016·Granted Jun 7, 2022·4 cites·16 claims
- 2188US7943767B2Fused bicyclic mTOR inhibitorsOSI PHARM INC·Filed 2009·Granted May 17, 2011·9 cites·14 claims
- 2288US7449478B2Indole compoundsNAT HEALTH RESEARCH INSTITUTES·Filed 2004·Granted Nov 11, 2008·27 cites·23 claims
- 2387US8846601B2Melanocortin receptor-specific peptidesSHI YI-QUN·Filed 2011·Granted Sep 30, 2014·5 cites·12 claims
- 2487US8796455B2Fused bicyclic mTOR inhibitorsCHEN XIN·Filed 2013·Granted Aug 5, 2014·8 cites·10 claims
- 2586US8729224B2Melanocortin receptor-specific peptides for treatment of female sexual dysfunctionPALATIN TECHNOLOGIES INC·Filed 2013·Granted May 20, 2014·7 cites·9 claims
- 2686US8183381B2N-linked heterocyclic receptor agonists for the treatment of diabetes and metabolic disordersMA JINGYUAN·Filed 2008·Granted May 22, 2012·13 cites·10 claims
- 2785US11427548B2Compounds and methods for the targeted degradation of androgen receptorARVINAS OPERATIONS INC·Filed 2019·Granted Aug 30, 2022·2 cites·15 claims
- 2885US8399433B2Amino pyrimidine anticancer compoundsAPPARI RAMA DEVI·Filed 2010·Granted Mar 19, 2013·16 cites·25 claims
- 2984US11512083B2Compounds and methods for the enhanced degradation of targeted proteinsARVINAS OPERATIONS INC·Filed 2020·Granted Nov 29, 2022·1 cites·17 claims
- 3084US8598374B2GPR120 receptor agonists and uses thereofMETABOLEX INC·Filed 2012·Granted Dec 3, 2013·6 cites·9 claims
- 3184US8487073B2Melanocortin receptor-specific peptides for treatment of sexual dysfunctionSHI YI-QUN·Filed 2010·Granted Jul 16, 2013·7 cites·12 claims
- 3284US8299117B2GPR120 receptor agonists and uses thereofSHI DONG FANG·Filed 2010·Granted Oct 30, 2012·5 cites·6 claims
- 3384US7687504B2Pyrrolidine compoundsNAT HEALTH RESEARCH INSTITUTES·Filed 2005·Granted Mar 30, 2010·6 cites·21 claims
- 3483US12006540B2Synthesis of novel disulfide linker based nucleotides as reversible terminators for DNA sequencing by synthesisUNIV COLUMBIA·Filed 2022·Granted Jun 11, 2024·0 cites·20 claims
- 3582US11959137B2Synthesis of novel disulfide linker based nucleotides as reversible terminators for DNA sequencing by synthesisUNIV COLUMBIA·Filed 2022·Granted Apr 16, 2024·0 cites·20 claims
- 3682US11266673B2Nucleotide derivatives and methods of use thereofUNIV COLUMBIA·Filed 2017·Granted Mar 8, 2022·2 cites·16 claims
- 3782US9096624B2Amino pyrimidine anticancer compoundsOSI PHARMACEUTICALS LLC·Filed 2013·Granted Aug 4, 2015·6 cites·7 claims
- 3882US2025223265A1Compounds and methods for the targeted degradation of androgen receptorARVINAS OPERATIONS INC·Filed 2024·Application pending·0 cites
- 3979US7371888B2α-(Trifluoromethyl-substituted aryloxy, arylamino, arylthio or arylmethyl)-trifluoromethyl-substituted phenylacetic acids and derivatives as antidiabetic agentsMETABOLEX INC·Filed 2005·Granted May 13, 2008·3 cites·10 claims
- 4079US2025092042A1Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereofNOVARTIS AG·Filed 2024·Application pending·0 cites
- 4178US12264157B2Compounds and methods for the enhanced degradation of targeted proteinsARVINAS OPERATIONS INC·Filed 2022·Granted Apr 1, 2025·0 cites·24 claims
- 4278US9737537B2Heterocyclic receptor agonists for the treatment of diabetes and metabolic disordersCYMABAY THERAPEUTICS INC·Filed 2016·Granted Aug 22, 2017·1 cites·2 claims
- 4378US9376494B2Antibodies to kallidin and des-Arg9-kallidinSANOFI SA·Filed 2013·Granted Jun 28, 2016·3 cites·13 claims
- 4478US2024309444A13'-o-modified nucleotide analogues with different cleavable linkers for attaching fluorescent labels to the base for dna sequencing by synthesisUNIV COLUMBIA·Filed 2024·Application pending·0 cites
- 4577US12188086B2Nucleotide analogues and use thereof for nucleic acid sequencing and analysis preliminary classUNIV COLUMBIA·Filed 2019·Granted Jan 7, 2025·1 cites·21 claims
- 4677US12157737B2Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereofNOVARTIS AG·Filed 2023·Granted Dec 3, 2024·0 cites·16 claims
- 4777US2024140959A12-azaspiro[3.4]octane derivatives as m4 agonistsNOVARTIS AG·Filed 2023·Application pending·0 cites
- 4877US2025236911A1Design and synthesis of novel disulfide linker based nucleotides as reversible terminators for dna sequencing by synthesisUNIV COLUMBIA·Filed 2025·Application pending·0 cites
- 4976US2024059686A1Compounds and methods for the targeted degradation of the androgen receptorARVINAS OPERATIONS INC·Filed 2022·Application pending·0 cites
- 5075US10465002B2Nucleic acids encoding antibodies to Kallidin and des-Arg10-Kallidin and host cells comprising the sameSANOFI SA·Filed 2017·Granted Nov 5, 2019·1 cites·15 claims
Showing the top 50 of 125 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Xin Chen files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →